Neuland Laboratories Ltd share price logo

Neuland Laboratories Ltd

NSE: NEULANDLAB

BSE: 524558

Small Cap

Pharma Sector

₹18944.00

-44.00

(-0.23%)

as on

bell
The current prices are delayed by 15 mins, login to check live prices.

Tech Chart

Neuland Laboratories Stock Performance

as on July 3, 2026 at 9:31 pm IST

  • Day's Low

    Day's High

    ₹18,747.00
    ₹19,200.00
    downward going graph

    1.04%

    Downside

    1.35%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    ₹11,500.00
    ₹19,747.00
    downward going graph

    39.29%

    Downside

    4.24%

    Upside

    downward going graph

Neuland Laboratories share price movements today

Previous Close
₹18,988.00
Open
₹19,100.00
Volume
75.14K
Upper Circuit
₹22,785.00
Lower Circuit
₹15,191.00
Day's Low - High
₹18,747.00 - ₹19,200.00
52 Week Low - High
₹11,500.00 - ₹19,747.00

Neuland Laboratories Historical Returns

1 Month Return
+ 12.36 %
3 Month Return
+ 43.28 %
1 Year Return
+ 57.88 %
3 Year Return
+ 538.8 %
5 Year Return
+ 780.97 %

Neuland Laboratories Fundamentals

as on July 3, 2026 at 4:01 pm IST

Market Cap

₹24,304.94 Cr

Return on Equity (ROE)

14.86

PE Ratio (TTM)

66.77

Return on capital employed (ROCE)

18.61

Industry PE ratio

48.13

Beta (LTM)

0.85

P/B Ratio

10.27

Dividend Yield

0.1

PEG Ratio

0.82

Quarterly Earnings Growth YOY

664.72

EPS (TTM)

201.63

Book Value

1181.32

Neuland Laboratories Stock Valuation

as on July 3, 2026 at 4:01 pm IST

Neuland Laboratories in the last 5 years

  • Overview

  • Trends

Lowest (10.19x)

March 30, 2020

Industry (48.13x)

July 3, 2026

Today (66.77x)

July 3, 2026

Highest (118.16x)

September 16, 2025

LowHigh

Today’s Price to Earnings Ratio: 66.77x

Neuland Laboratories Technical Analysis

Track how Neuland Laboratories technical analysis has moved over time to understand its trends.

1 min
5 min
15 min
30 min
1 day
1 week
1 month

Technicals Summary

Bearish

Neutral

Bullish

Bearish

Moving Averages

Bearish

Neutral

Bullish

Bearish

Oscillators

Bearish

Neutral

Bullish

Bearish

Overall

Bearish11
Bullish1
Neutral3

Oscillators

Name

Value

Action

MACD level (12,26)
-12.68
Bearish
CCI (20)
-64.39
Neutral
RSI (14)
26.29
Bullish
Momentum (10)
-29
Neutral
ADI (14)
79.54
Bearish
Ultimate Oscillator (7,14,28)
41.78
Neutral

Moving Averages

Name

Value

Action

SMA (20)
18916.2
Bearish
EMA (20)
18913.3
Bearish
VWMA (20)
18908.35
Bearish
SMA (50)
18940.4
Bearish
EMA (50)
18933.27
Bearish
SMA (200)
18958.2
Bearish
EMA (200)
18959.69
Bearish
KAMA (200)
18927.49
Bearish
DEMA (200)
18935.24
Bearish

Neuland Laboratories Ltd vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Neuland Laboratories with its industry peers.

Company
Analyst View
Market Cap(in ₹ Cr)
5 Year CAGRDebt to Asset Ratio
Net Profit(in ₹ Cr)
Yearly Revenue(in ₹ Cr)
Neuland Laboratories Ltd image
Neuland Laboratories Ltd
BUY24,304.94156.19%0.552601,476
Marksans Pharma Ltd image
Marksans Pharma Ltd
BUY11,983.9238.22%0.563822,622
Caplin Point Laboratories Ltd image
Caplin Point Laboratories Ltd
BUY19,292.5353.96%0.515411,937
Rubicon Research Ltd image
Rubicon Research Ltd
BUY21,615.5321.61%0.731341,284
OneSource Specialty Pharma Ltd image
OneSource Specialty Pharma Ltd
BUY19,134.38-0.48%0.57-181,444
See all

Market expectation of Neuland Laboratories Stock

Common consensus of the market based on various publicly available news, publications,brokerage expectation and market data

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Neuland Laboratories Stock’s Investor Sentiment and Interest

Search interest for Neuland Laboratories Ltd Stock has decreased by -45% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-45% versus previous 30 day period

Neuland Laboratories Ltd Quarterly Profit & Loss

Figures in Rupees Crores

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Sales
417.75
392.83
385.01
439.6
310.84
398.03
328.36
292.75
514.27
439.71
776.25
Other Income
3.05
2.1
5.36
25.43
4.33
59.68
7.46
7.86
1.8
8.05
12.46
Total Income
420.8
394.93
390.37
465.03
315.18
457.72
335.82
300.61
516.07
447.76
788.71
Expenses
280.26
271.56
278.09
316.24
248.62
311.43
277.29
258.26
358.73
362.58
468.92
Operating Profit
137.49
121.27
106.92
123.36
62.22
86.6
51.07
34.49
155.54
77.13
307.33
Operating Profit Margin %
32.91%
30.87%
27.77%
28.06%
20.02%
21.76%
15.55%
11.78%
30.24%
17.54%
39.59%
Profit Before Interest, Tax and Depreciation
140.54
123.37
112.27
148.79
66.56
146.28
58.54
42.34
157.35
85.19
319.79
Interest
4.43
3.74
3.61
2.67
1.06
2.22
2.35
4.58
5.37
6.79
7.21
Depreciation
14.51
15.14
16.46
16.28
16.07
16.3
16.89
20.19
22.54
23.92
25.09
Profit Before Tax
121.6
104.49
92.2
129.84
49.43
127.76
39.3
17.57
129.44
54.48
287.49
Tax Paid
32.34
23.09
24.64
31.97
16.58
26.18
11.49
3.67
32.58
13.9
74.82
Profit After Tax
89.25
81.39
67.56
97.87
32.84
101.59
27.81
13.9
96.85
40.57
212.67
Total Net profit including share of profit / Loss from associate company
89.25
81.39
67.56
97.87
32.84
101.59
27.81
13.9
96.85
40.57
212.67
EPS
69.56
63.44
52.66
76.28
25.6
79.18
21.67
10.83
75.49
31.62
165.76
Actual EPS
69.56
63.44
52.66
76.28
25.6
79.18
21.67
10.83
75.49
31.62
165.76
Adjusted EPS
69.56
63.44
52.66
76.28
25.6
79.18
21.67
10.83
75.49
31.62
165.76
Diluted EPS
69.56
63.44
52.66
76.28
25.6
79.18
21.67
10.83
75.49
31.62
165.76

Neuland Laboratories Ltd Annual Profit & Loss

Figures in Rupees Crores

Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Sales
527.41
666.83
762.71
936.91
951.08
1,191.2
1,558.58
1,476.84
2,022.99
Other Income
4.53
3.49
3.89
16.1
2.08
9.75
12.54
96.91
30.17
Total Income
531.94
670.32
766.6
953.01
953.15
1,200.95
1,571.12
1,573.75
2,053.15
Expenses
476.98
608.46
660.82
790.09
808.46
919.36
1,095.99
1,153.58
1,448.49
Operating Profit
50.43
58.37
101.89
146.82
142.62
271.84
462.59
323.26
574.5
Operating Profit Margin %
9.56%
8.75%
13.36%
15.67%
15%
22.82%
29.68%
21.89%
28.4%
Profit Before Interest, Tax and Depreciation
54.97
61.86
105.78
162.91
144.7
281.59
475.13
420.17
604.66
Interest
18.93
15.66
21.57
17.9
13.5
13.07
14
8.3
23.95
Depreciation
22.1
25.86
31.28
39.68
49.04
52.78
59.7
65.55
91.74
Profit Before Tax
13.94
20.34
52.93
105.33
82.16
215.74
401.43
346.32
488.97
Tax Paid
1.87
3.9
36.72
24.71
18.34
52.23
101.36
86.22
124.98
Profit After Tax
12.06
16.44
16.21
80.63
63.82
163.52
300.08
260.11
364
Total Net profit including share of profit / Loss from associate company
12.06
16.44
16.21
80.63
63.82
163.52
300.08
260.11
364
EPS
10.81
13.06
12.63
62.85
49.74
127.45
233.89
202.74
283.71
Actual EPS
10.81
13.06
12.63
62.85
49.74
127.45
233.89
202.74
283.71
Adjusted EPS
10.81
13.06
12.63
62.85
49.74
127.45
233.89
202.74
283.71
Diluted EPS
10.81
13.06
12.63
62.85
49.74
127.45
233.89
202.74
283.71

Neuland Laboratories Ltd Cash Flow

Figures in Rupees Crores

Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Net Cash from Operating Activities
44.83
38.68
11.27
69.91
57.34
189.36
60.39
237.21
261.18
317.38
Cash Flow from Investing Activities
-19.86
-42.12
-116.28
-77.23
-48.6
-84.47
-95.45
-61.09
-149.74
-297.99
Cash Flow from Financing Activities
-23.62
-0.09
104.84
11.99
-5.48
-113.68
37.73
-135.79
-69.28
24.96
Net Cash Flow
1.35
-3.52
-0.16
4.65
3.27
-8.77
2.66
40.32
42.16
44.36

Neuland Laboratories Stock Shareholding Pattern

Numbers in percentages

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Promoters
35.97%
32.8%
32.74%
32.72%
32.64%
32.68%
32.68%
32.68%
32.64%
32.63%
32.63%
DII
6.99%
6.03%
6.54%
6.39%
6.38%
9.08%
10.97%
11.57%
13.54%
14.71%
15.84%
FII
21.57%
22.69%
24.44%
25.72%
26.46%
23.86%
22.11%
21.69%
20.6%
20.9%
20.46%
Government
0.4%
0.4%
0.4%
0.4%
0.4%
0.4%
0.4%
0.4%
0.4%
0%
0%
Public
35.07%
38.08%
35.88%
34.76%
34.11%
33.98%
33.84%
33.67%
32.81%
31.76%
31.07%
Total Outstanding Shares
1,28,29,889
1,28,29,889
1,28,29,889
1,28,29,889
1,28,29,889
1,28,29,889
1,28,29,889
1,28,29,889
1,28,29,889
1,28,29,889
1,28,29,889
Total Shareholders
26,824
27,723
28,616
29,077
34,567
39,315
39,333
42,419
44,393
46,187
46,304

Mutual Funds that own Neuland Laboratories Stock

Check out the Mutual Funds with significant holdings in Neuland Laboratories.

Neuland Laboratories Corporate Actions

View detailed summary of the earnings and dividend history of Neuland Laboratories.

  • Neuland Laboratories Ltd Earnings Results

    Neuland Laboratories Ltd’s net profit jumped 664.72% since last year same period to ₹212.67Cr in the Q4 2025-2026. On a quarterly growth basis, Neuland Laboratories Ltd has generated 424.21% jump in its net profits since last 3-months.

    Read More about Earnings Results

  • Neuland Laboratories Ltd Dividends May,2026

    In the quarter ending March 2026, Neuland Laboratories Ltd has declared dividend of ₹34.00 per share on 12 May 2026 - translating a dividend yield of 0.24%.

    Read More about Dividends

Indices Featuring Neuland Laboratories Stock

Check stock indices that include Neuland Laboratories.

S&P BSE SmallCap Select

₹8,726.76

-28.77 (▲0.33%)

S&P BSE 400 MidSmallCap

₹12,588.23

-17.06 (▲0.14%)

BSE Healthcare

₹50,088.47

646.70 (▲1.31%)

Nifty Small 100

₹19,175.10

7.30 (▲0.04%)

Nifty 500

₹23,301.15

36.35 (▲0.16%)

Nifty MidSmallcap 400

₹21,111.00

-25.35 (▲0.12%)

Nifty Smallcap 250

₹17,996.25

12.90 (▲0.07%)

Nifty Smallcap 50

₹9,470.40

10.40 (▲0.11%)

BSE 500

₹36,431.45

55.43 (▲0.15%)

S&P BSE 250 SmallCap

₹7,120.39

6.41 (▲0.09%)

Insights on Neuland Laboratories Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, 40.57 Cr → 212.67 Cr (in ₹), with an average increase of 80.9% per quarter

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, NEULANDLAB has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, NEULANDLAB stock has moved up by 57.9%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, NEULANDLAB has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 447.76 Cr → 788.71 Cr (in ₹), with an average increase of 43.2% per quarter

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 10.39% to 11.35% in Mar 2026 quarter

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 32.63% of holdings in Mar 2026 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 31.76% to 31.07% in Mar 2026 quarter

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 20.90% to 20.46% in Mar 2026 quarter

About Neuland Laboratories Ltd

Neuland Laboratories NLL, a private limited company founded in 1984, manufactures bulk drugs, such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin, which are exported to more than 35 countries. To part finance capacity expansion and diversify its product-mix, NLL made an initial public offering in 1994 for Rs 5.69 crores. The Research & Development has developed a process to manufacture Oflaxacin for Regulatory Markets, and the Pashamylaram unit received USFDA approval for Rantidine Hydrochloride Form. During the years 1992-2000 the company introduced Itraconazole, an antifungal drug, Ipratropium Bromide, an antiasthmatic drug, Mirtrazapine, an antidepressive drug, and Ramipril, a cardiovascular drug, while in 2001 it increased its capacity of Ciprofloxacin and Ranitidine with financial assistance from IDBI of Rs.65 lacs. In 2002, it commenced production of Ramipril and in 2003 of Citalopram Hydrobromide, Pirbuterol Acetate, Levofloxacin and Levetiracetam. Furthermore, Neuland Laboratories Ltd has a subsidiary in Delaware USA and in Japan (2008-2009). Neuland Laboratories NLL is thus well-positioned in the bulk drugs market and is continuously striving to expand its product mix with the help of innovation in research and development.

Revenue: ₹776.25Cr as on March 2026 (Q4 FY26)
Net Profit: ₹212.67Cr as on March 2026 (Q4 FY26)
Listing date: 17 May, 1995
Chairperson Name: D Saharsh Rao
OrganisationNeuland Laboratories Ltd
HeadquartersHyderabad
IndustryPharmaceuticals
CEOD Saharsh Rao
E-voting on sharesClick here to vote

FAQs

What is Neuland Laboratories share price today?

Neuland Laboratories share price today stands at ₹18944 as on at the close of the market. Neuland Laboratories share today touched a day high of ₹19200 and a low of ₹18747.

What is the 52 week high and 52 week low range for Neuland Laboratories share?

Neuland Laboratories touched a 52 week high of ₹19747 and a 52 week low of ₹11500. Neuland Laboratories share price today i.e. is closed at ₹18944, which is -4.07% down from its 52 week high and 64.73% up from its 52 week low.

What is Neuland Laboratories's market capitalisation today?

Neuland Laboratories market capitalisation is ₹24,304.94 Cr as on .

How to buy Neuland Laboratories shares?

To buy Neuland Laboratories shares, you need to follow these steps:

  • Open a Demat account and Trading account on INDmoney
  • Fund your Trading account
  • Search for NEULANDLAB or Neuland Laboratories Ltd on the INDmoney app to check live prices of the stock
  • Click on Buy or SIP to place an order to invest in Neuland Laboratories shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

What is Neuland Laboratories trading volume today?

Neuland Laboratories trading volume is 75.14K as on . This means that 75.14K shares of Neuland Laboratories were bought and sold on the stock market during today's trading session.